Clinical trial
Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of…
NCT00229112 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00229112 |
|---|---|
| Title | Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034) |
| Official title | A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults. |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Foot Infections in Diabetic Patients |
| Intervention type | Drug |
| Interventions | MK0826, ertapenem sodium / Duration of Treatment - 24 weeks, Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks |
| Enrollment | 400 |
| Start date | Apr 1, 2001 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | Sep 29, 2005 |
| Last update posted | Feb 17, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: